Cordis Stresses Durability Of Fortron AAA System, European Safety Results
This article was originally published in The Gray Sheet
Executive Summary
The positive safety profile of Johnson & Johnson/ Cordis' Fortron abdominal aortic aneurysm (AAA) stent graft, as demonstrated in Europe, likely will be a key component of the firm's U.S. marketing strategy
You may also be interested in...
Guidant Likely Will Bow Out Of AAA Race As Stakes Rise Too High
Guidant is poised to exit the abdominal aortic aneurysm market, which could eventually reach $1 bil., citing declining sales and a lack of adoption by vascular surgeons of its Ancure AAA endovascular stent graft
Medtronic Talent Stent Graft Draws MDA Alert; Firm Eyes 2003 U.S. Launch
The UK Medical Devices Agency expects Medtronic to make available a re-designed version of the Talent abdominal aortic aneurysm (AAA) stent graft soon, following reported post-implantation device fractures in U.S. premarket clinical trials
J&J/Cordis Teramed Alliance Suggests Swifter Access To $1 Bil. AAA Market
Johnson & Johnson/Cordis will join a crowded field of players in the worldwide abdominal aortic aneurysm (AAA) market, expected to top $1 bil. by 2008, following the acquisition of privately-held Teramed